Table 2.
Statistical analysis of PASI-75 response and PGA score (%)
| Monotherapy etanercept (n = 15) | Absolute numbers | Combination therapy etanercept with fumarates (n = 18) | Absolute numbers | p value | |
|---|---|---|---|---|---|
| PASI-75 at week 12 | 64 (39–89) | 9 out of 14 | 67 (42–91) | 12 out of 18 | 1.00a |
| PASI-75 at week 24 | 57 (31–83) | 8 out of 14 | 78 (59–97) | 14 out of 18 | 0.27b |
| PASI-75 at week 48 | 64 (42–86) | 9 out of 14 | 87 (70–104) | 13 out of 15 | 0.22b |
| PGA (clear/almost clear) at week 12 | 57 (31–83) | 8 out of 14 | 89 (74–103) | 16 out of 18 | 0.096b |
| PGA (clear/almost clear) at week 24 | 64 (39–89) | 9 out of 14 | 94 (84–105) | 17 out of 18 | 0.064b |
| PGA (clear/almost clear) at week 48 | 64 (39–89) | 9 out of 14 | 87 (70–104) | 13 out of 15 | 0.22b |
Results are expressed as means with 95% confidence intervals in parentheses. Missing data: 1 patient in the monotherapy group had missing visits at weeks 12 and 24; 1 patient in the monotherapy group and 3 patients in the combination therapy group were lost to follow-up at week 48. As a consequence, these patients were not included in the statistical analysis of the PASI-75 and PGA score.
a
χ2 test.
b
Fisher's exact test.